One universal common endpoint in mouse models of amyotrophic lateral sclerosis

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Solomon, Jesse A ^a   Tarnopolsky, Mark A ^b   Hamadeh, Mazen J ^a,b  

^a York University   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CORRELATION ANALYSIS; DISEASE MODEL; DRUG RESEARCH; GENERAL CONDITION DETERIORATION; HINDLIMB; LOG RANK TEST; MOTONEURON; MOUSE; NERVE CELL NECROSIS; NEUROMUSCULAR DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PARALYSIS; PROPRIOCEPTION; QUALITY OF LIFE; RESEARCH ETHICS; RIGHTING REFLEX; SYSTEMATIC ERROR; WEIGHT REDUCTION; ANIMAL; BIOASSAY; FEMALE; GENETICS; MALE; MENTAL STRESS; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REPRODUCIBILITY; SURVIVAL; TRANSGENIC MOUSE;

ANIMALIA; MUS; RODENTIA;

SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; ENDPOINT DETERMINATION; FEMALE; HINDLIMB; MALE; MICE; MICE, TRANSGENIC; PARALYSIS; REFLEX, RIGHTING; REPRODUCIBILITY OF RESULTS; STRESS, PSYCHOLOGICAL; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS;

EID: 79958110399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020582     Document Type: Article

References (116)

1. Mahoney DJ, Rodriguez C, Devries M, Yasuda N, Tarnopolsky MA, (2004) Effects of high-intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis. Muscle Nerve 29: 656-662.
2. Lee J, Ryu H, Kowall NW, (2009) Motor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS mice. Biochem Biophys Res Commun 384: 524-529.
3. Liebetanz D, Hagemann K, von Lewinski F, Kahler E, Paulus W, (2004) Extensive exercise is not harmful in amyotrophic lateral sclerosis. Eur J Neurosci 20: 3115-20.
4. Martinez JA, Francis GJ, Liu WQ, Pradzinsky N, Fine J, et al. (2008) Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis. Neuroscience 157: 908-925.
5. Matthews RT, Yang L, Browne S, Baik M, Beal MF, (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A 95: 8892-8897.
6. Mattson MP, Cutler RG, Camandola S, (2007) Energy intake and amyotrophic lateral sclerosis. Neuromolecular Med 9: 17-20.
7. Moges H, Vasconcelos OM, Campbell WW, Borke RC, McCoy JA, et al. (2009) Light therapy and supplementary Riboflavin in the SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis (FALS). Lasers Surg Med 41: 52-59.
8. Nagano S, Fujii Y, Yamamoto T, Taniyama M, Fukada K, et al. (2003) The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp Neurol 179: 176-180.
9. Nagano S, Ogawa Y, Yanagihara T, Sakoda S, (1999) Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett 265: 159-162.
10. Neymotin A, Petri S, Calingasan NY, Wille E, Schafer P, et al. (2009) Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 220: 191-197.
11. Ohnishi S, Ito H, Suzuki Y, Adachi Y, Wate R, et al. (2009) Intra-bone marrow-bone marrow transplantation slows disease progression and prolongs survival in G93A mutant SOD1 transgenic mice, an animal model mouse for amyotrophic lateral sclerosis. Brain Res 1296: 216-224.
12. Ohta Y, Kamiya T, Nagai M, Nagata T, Morimoto N, et al. (2008) Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res 86: 3028-3037.
13. Pamphlett R, Todd E, Vink R, McQuilty R, Cheema SS, (2003) Magnesium supplementation does not delay disease onset or increase survival in a mouse model of familial ALS. J Neurol Sci 216: 95-98.
14. Park JH, Hong YH, Kim HJ, Kim SM, Kim MJ, et al. (2007) Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neurosci Lett 413: 265-269.
15. Patel BP, Safdar A, Raha S, Tarnopolsky MA, Hamadeh MJ, (2010) Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS. PLoS One Feb 24;5 (2): e9386.
16. Pedersen WA, Mattson MP, (1999) No benefit of dietary restriction on disease onset or progression in amyotrophic lateral sclerosis Cu/Zn-superoxide dismutase mutant mice. Brain Res 833: 117-120.
17. Petri S, Kiaei M, Wille E, Calingasan NY, Flint Beal M, (2006) Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice. J Neurol Sci 251: 44-49.
18. Petri S, Calingasan NY, Alsaied OA, Wille E, Kiaei M, et al. (2007) The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 102: 991-1000.
19. Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, et al. (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22: 40-49.
20. Pitzer C, Kruger C, Plaas C, Kirsch F, Dittgen T, et al. (2008) Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 131: 3335-3347.
21. Pizzasegola C, Caron I, Daleno C, Ronchi A, Minoia C, et al. (2009) Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 10: 221-228.
22. Poduslo JF, Whelan SL, Curran GL, Wengenack TM, (2000) Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics. Ann Neurol 48: 943-947.
23. Reinholz MM, Merkle CM, Poduslo JF, (1999) Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol 159: 204-216.
24. Rembach A, Turner BJ, Bruce S, Cheah IK, Scott RL, et al. (2004) Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. J Neurosci Res 77: 573-582.
25. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.[Erratum appears in J Neurochem. 2006 Feb;96(3):908]. J Neurochem 93: 1087-1098.
26. Sekiya M, Ichiyanagi T, Ikeshiro Y, Yokozawa T, (2009) The Chinese prescription Wen-Pi-Tang extract delays disease onset in amyotrophic lateral sclerosis model mice while attenuating the activation of glial cells in the spinal cord. Biol Pharm Bull 32: 382-388.
27. Shimojo Y, Kosaka K, Noda Y, Shimizu T, Shirasawa T, (2010) Effect of rosmarinic acid in motor dysfunction and life span in a mouse model of familial amyotrophic lateral sclerosis. J Neurosci Res 88: 896-904.
28. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL, (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101: 87-98.
29. Snow RJ, Turnbull J, da Silva S, Jiang F, Tarnopolsky MA, (2003) Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience 119: 661-667.
30. Suchy J, Lee S, Ahmed A, Shea TB, (2010) Dietary supplementation with S-adenosyl methionine delays the onset of motor neuron pathology in a murine model of amyotrophic lateral sclerosis. Neuromolecular Med 12: 86-97.
31. Teng YD, Choi H, Huang W, Onario RC, Frontera WR, et al. (2006) Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis. Neurosci Lett 397: 155-158.
32. Tokuda E, Ono S, Ishige K, Watanabe S, Okawa E, et al. (2008) Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol 213: 122-128.
33. Turner BJ, Parkinson NJ, Davies KE, Talbot K, (2009) Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol Dis 34: 511-517.
34. Turner BJ, Rembach A, Spark R, Lopes EC, Cheema SS, (2003) Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. J Neurosci Res 74: 605-613.
35. Turner BJ, Murray SS, Piccenna LG, Lopes EC, Kilpatrick TJ, et al. (2004) Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. J Neurosci Res 78: 193-199.
36. Van Damme P, Leyssen M, Callewaert G, Robberecht W, Van Den Bosch L, (2003) The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett 343: 81-84.
37. Veldink JH, Bar PR, Joosten EAJ, Otten M, Wokke JHJ, et al. (2003) Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul Disord 13: 737-743.
38. Vercelli A, Mereuta OM, Garbossa D, Muraca G, Mareschi K, et al. (2008) Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 31: 395-405.
39. Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC, (2004) Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 251: 1080-1084.
40. Wang R, Zhang D, (2005) Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 22: 2376-2380.
41. Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, et al. (2006) Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41: 313-323.
42. West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, et al. (2004) The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem 91: 133-143.
43. Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, et al. (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 85: 142-150.
44. Xu Z, Chen S, Li X, Luo G, Li L, et al. (2006) Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochem Res 31: 1263-1269.
45. Zhang X, Chen S, Li L, Wang Q, Le W, (2008) Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice. Neuropharmacology 54: 1112-1119.
46. Zhao Z, Lange DJ, Voustianiouk A, MacGrogan D, Ho L, et al. (2006) A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci 7: 29.
47. Amante DJ, Kim J, Carreiro ST, Cooper AC, Jones SW, et al. (2010) Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice. Amyotroph Lateral Scler 2010 Jun 22 [Epub ahead of print].
48. Amodio R, Esposito E, De Ruvo C, Bellavia V, Amodio E, et al. (2006) Red wine extract prevents neuronal apoptosis in vitro and reduces mortality of transgenic mice. Ann N Y Acad Sci 1089: 88-97.
49. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI, (2000) N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 11: 2491-2493.
50. Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, et al. (2001) Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 77: 383-390.
51. Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D, et al. (2001) Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp Neurol 168: 419-424.
52. Azari MF, Profyris C, Le Grande MR, Lopes EC, Hirst J, et al. (2005) Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. Eur J Neurol 12: 357-364.
53. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429: 413-417.
54. Barbeito AG, Martinez-Palma L, Vargas MR, Pehar M, Manay N, et al. (2010) Lead exposure stimulates VEGF expression in the spinal cord and extends survival in a mouse model of ALS. Neurobiol Dis 37: 574-580.
55. Bruce KM, Narayan K, Kong HC, Larmour I, Lopes EC, et al. (2004) Chemotherapy delays progression of motor neuron disease in the SOD1 G93A transgenic mouse. Chemotherapy 50: 138-142.
56. Bruestle DA, Cutler RG, Telljohann RS, Mattson MP, (2009) Decline in daily running distance presages disease onset in a mouse model of ALS. Neuromolecular Med 11: 58-62.
57. Caraganis A, Benn S, Cudkowicz M, Brown RH Jr, (2008) Thrombopoietin is ineffective in a mouse model of motor neuron disease. Amyotroph Lateral Scler 9: 354-358.
58. Chiba T, Yamada M, Sasabe J, Terashita K, Aiso S, et al. (2006) Colivelin prolongs survival of an ALS model mouse. Biochem Biophys Res Commun 343: 793-798.
59. Choi CI, Lee YD, Gwag BJ, Cho SI, Kim SS, et al. (2008) Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J Neurol Sci 268: 40-47.
60. Chritin M, Savasta M, Besson G, (2006) Benefit of tianeptine and morphine in a transgenic model of familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 7: 32-37.
61. Ciriza J, Moreno-Igoa M, Calvo AC, Yague G, Palacio J, et al. (2008) A genetic fusion GDNF-C fragment of tetanus toxin prolongs survival in a symptomatic mouse ALS model. Restor Neurol Neurosci 26: 459-465.
62. Corti S, Locatelli F, Papadimitriou D, Del Bo R, Nizzardo M, et al. (2007) Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. Brain 130: 1289-1305.
63. Crochemore C, Virgili M, Bonamassa B, Canistro D, Pena-Altamira E, et al. (2009) Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis. Muscle Nerve 39: 548-552.
64. Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF, (2005) Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258-265.
65. Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, et al. (2009) Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler 10: 85-94.
66. Derave W, Van Den Bosch L, Lemmens G, Eijnde BO, Robberecht W, et al. (2003) Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol Dis 13: 264-272.
67. Ende N, Weinstein F, Chen R, Ende M, Ende N, (2000) Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sci 67: 53-59.
68. Ermilova IP, Ermilov VB, Levy M, Ho E, Pereira C, et al. (2005) Protection by dietary zinc in ALS mutant G93A SOD transgenic mice. Neurosci Lett 379: 42-46.
69. Esposito E, Rossi C, Amodio R, Di Castelnuovo A, Bendotti C, et al. (2000) Lyophilized red wine administration prolongs survival in an animal model of amyotrophic lateral sclerosis. Ann Neurol 48: 686-687.
70. Esposito E, Capasso M, di Tomasso N, Corona C, Pellegrini F, et al. (2007) Antioxidant strategies based on tomato-enriched food or pyruvate do not affect disease onset and survival in an animal model of amyotrophic lateral sclerosis. Brain Res Sep 7;1168: 90-6 Epub 2007 Jul 31.
71. Ferrante RJ, Klein AM, Dedeoglu A, Beal MF, (2001) Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J Mol Neurosci 17: 89-96.
72. Fischer LR, Culver DG, Davis AA, Tennant P, Wang M, et al. (2005) The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis 19: 293-300.
73. Ghoddoussi F, Galloway MP, Jambekar A, Bame M, Needleman R, et al. (2010) Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and glutamate in a mouse model of ALS. J Neurol Sci 290: 41-47.
74. Gifondorwa DJ, Robinson MB, Hayes CD, Taylor AR, Prevette DM, et al. (2007) Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. J Neurosci 27: 13173-13180.
75. Groeneveld GJ, de Leeuw van Weenen J, van Muiswinkel FL, Veldman H, Veldink JH, et al. (2003) Zinc amplifies mSOD1-mediated toxicity in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett 352: 175-178.
76. Groeneveld GJ, Van Muiswinkel FL, Sturkenboom JM, Wokke JH, Bar PR, et al. (2004) Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS. Brain Res 1021: 128-131.
77. Gros-Louis F, Soucy G, Lariviere R, Julien JP, Gros-Louis F, et al. (2010) Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 113: 1188-1199.
78. Gurney ME, Fleck TJ, Himes CS, Hall ED, (1998) Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 50: 62-66.
79. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, et al. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147-157.
80. Habisch HJ, Schwalenstocker B, Danzeisen R, Neuhaus O, Hartung HP, et al. (2007) Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS. Exp Neurol 206: 288-295.
81. Haenggeli C, Julien JP, Mosley RL, Perez N, Dhar A, et al. (2007) Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol Dis 26: 146-152.
82. Hamadeh MJ, Tarnopolsky MA, (2006) Transient caloric restriction in early adulthood hastens disease endpoint in male, but not female, Cu/Zn-SOD mutant G93A mice. Muscle Nerve 34: 709-719.
83. Hamadeh MJ, Rodriguez MC, Kaczor JJ, Tarnopolsky MA, (2005) Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve 31: 214-220.
84. Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, et al. (2008) Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213: 448-455.
85. Jaarsma D, Guchelaar HJ, Haasdijk E, de Jong JM, Holstege JC, (1998) The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis. Ann Neurol 44: 293.
86. Jiang F, DeSilva S, Turnbull J, (2000) Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. J Neurol Sci 180: 52-54.
87. Joo IS, Hwang DH, Seok JI, Shin SK, Kim SU, (2007) Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Clin Neurol 3: 181-186.
88. Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, et al. (2008) Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 107: 339-350.
89. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF, (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191: 331-336.
90. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, et al. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10: 402-405.
91. Kim K, Moore DH, Makriyannis A, Abood ME, (2006) AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542: 100-105.
92. Kira Y, Nishikawa M, Ochi A, Sato E, Inoue M, (2006) L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res 1070: 206-214.
93. Kirkinezos IG, Hernandez D, Bradley WG, Moraes CT, (2003) Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosis. Ann Neurol 53: 804-807.
94. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, et al. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5: 347-350.
95. Koh SH, Kim Y, Kim HY, Cho GW, Kim KS, et al. (2007) Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation. Eur J Neurosci 25: 1923-1930.
96. Koh SH, Kim Y, Kim HY, Hwang S, Lee CH, et al. (2007) Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp Neurol 205: 336-346.
97. Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ, et al. (2006) The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett 395: 103-107.
98. Shaw PJ, (1999) Motor neurone disease. BMJ 318: 1118-1121.
99. Martin LJ, (1999) Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 58: 459-471.
100. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.[Erratum appears in Science 1995 Jul 14;269(5221):149]. Science 264: 1772-1775.
101. Canadian Council on Animal Care (1998) CCAC guidelines on: choosing an appropriate endpoint in experiments using animals for research, teaching and testing.
102. Guo YS, Wu DX, Wu HR, Wu SY, Yang C, et al. (2009) Sensory involvement in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Exp Mol Med 41: 140-150.
103. Orrell RW, King AW, Hilton DA, Campbell MJ, Lane RJ, et al. (1995) Familial amyotrophic lateral sclerosis with a point mutation of SOD-1: intrafamilial heterogeneity of disease duration associated with neurofibrillary tangles. J Neurol Neurosurg Psychiatry 59: 266-270.
104. Seevaratnam R, Raha S, Tarnopolsky MA, Hamadeh MJ, (2009) Coffee increases antioxidant enzyme capacity in the brain of male G93A mice, an animal model of amyotrophic lateral sclerosis (ALS). FASEB J 23: 109.6.
105. Seevaratnam R, Raha S, Tarnopolsky MA, Hamadeh MJ, (2009) Caffeine reduces motor performance and antioxidant enzyme capacity in the brain of female G93A mice, an animal model of amyotrophic lateral sclerosis (ALS). FASEB J 23: 963.3.
106. Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, et al. (2004) Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 20: 3179-3183.
107. Holzbaur EL, Howland DS, Weber N, Wallace K, She Y, et al. (2006) Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis 23: 697-707.
108. Kawamura Y, Dyck PJ, Shimono M, Okazaki H, Tateishi J, et al. (1981) Morphometric comparison of the vulnerability of peripheral motor and sensory neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 40: 667-675.
109. Tateishi T, Hokonohara T, Yamasaki R, Miura S, Kikuchi H, et al. (2010) Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol 119: 355-364.
110. Sasaki S, Horie Y, Iwata M, (2007) Mitochondrial alterations in dorsal root ganglion cells in sporadic amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 114: 633-639.
111. Hirano A, Kurland LT, Sayre GP, (1967) Familial amyotrophic lateral sclerosis. A subgroup characterized by posterior and spinocerebellar tract involvement and hyaline inclusions in the anterior horn cells. Arch Neurol 16: 232-243.
112. Suzuki M, Irie T, Watanabe T, Mikami H, Yamazaki T, et al. (2008) Familial amyotrophic lateral sclerosis with Gly93Ser mutation in Cu/Zn superoxide dismutase: a clinical and neuropathological study. J Neurol Sci 268: 140-144.
113. Dal Canto MC, Gurney ME, (1994) Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 145: 1271-1279.
114. Butterfield RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, et al. (1999) Genetic Analysis of Disease Subtypes and Sexual Dimorphisms in Mouse Experimental Allergic Encephalomyelitis (EAE): Relapsing/Remitting and Monophasic Remitting/Nonrelapsing EAE Are Immunogenetically Distinct. J Immunol 162: 3096-3102.
115. Fleming KK, Bovaird JA, Mosier MC, Emerson MR, LeVine SM, et al. (2005) Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J Neuroimmunol 170: 71-84.
116. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, et al. (2007) IL-23 Is Critical in the Induction but Not in the Effector Phase of Experimental Autoimmune Encephalomyelitis. J Immunol 178: 2589-2598.